This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers (RemiCaps2)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Medical University of Vienna.
Recruitment status was:  Recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: November 10, 2008
Last updated: May 20, 2009
Last verified: May 2009

Treatment of chronic pain is a major clinical challenge since chronic pain is frequent and leads to deterioration of quality of life. An injury or wound can lead to long term changes in the nervous system that make the skin more sensitive at and near the injury; this is termed hyperalgesia and occurs through long term depotentiation (LTP), i.e., a change in the synaptic interaction between neurons.

Opioids are the gold standard for the symptomatic therapy of moderate to severe pain. Now, in animal studies the investigators have discovered previously unrecognized effects of opioids.

Intradermal injection of capsaicin (injection of pepper extract into the skin) is an established pain model in humans. The investigators want to test the influence of remifentanil, an ultra-short acting opioid, on hyperalgesia observed after intradermal capsaicin in human volunteers in a double blind cross-over prospective active placebo controlled clinical trial.

Condition Intervention Phase
Hyperalgesia Drug: Remifentanil Drug: Midazolam Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Area of pin prick hyperalgesia [ Time Frame: 0-6 hours ]

Secondary Outcome Measures:
  • Stimulus-response (SR)function to a set of modified rigid von Frey filaments (8-512 mN) [ Time Frame: 0-6 hours ]
  • Pain immediately after injection [ Time Frame: 0-15 minutes ]
  • Heat pain threshold within the area of mechanical hyperalgesia [ Time Frame: 0-6 hours ]
  • Mechanical pain threshold within the area of pin prick hyperalgesia, area of dynamic allodynia to brush [ Time Frame: 0-6 hours ]
  • Adverse effects [ Time Frame: 10 and 30 min after infusion of study medication ]

Estimated Enrollment: 24
Study Start Date: November 2008
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Remifentanil Drug: Remifentanil
Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
Placebo Comparator: Midazolam
Active Placebo
Drug: Midazolam
Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µ over 10 minutes to mimic typical central nervous side effects of remifentanil.


Ages Eligible for Study:   19 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index between 15th and 85th percentile
  • Normal findings in the medical history and physical examination
  • Drug free for 1 week prior to the study day

Exclusion Criteria:

  • Regular use of medication especially analgesics
  • Abuse of alcoholic beverages, drug abuse
  • History of asthma
  • Participation in a clinical trial in the 2 weeks preceding the study
  • Symptoms of a clinically relevant illness in the 2 weeks before the first study day
  • Resting systolic blood pressure > 135 mmHg or diastolic blood pressure > 85 mmHg
  • Acute skin diseases like sunburn on the relevant areas or skin lesions
  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00789386

Contact: Michael H Andreae, MD +436769677181
Contact: Bernd Schudermaier, M.Pharm +43140400 ext 6428

Department of Anaesthesia, Medical University of Vienna Recruiting
Vienna, Austria, 1090
Principal Investigator: Astrid Chiari, MD         
Sub-Investigator: Burkhard Gustorff, MD         
Sub-Investigator: Bernd Schmudermaier, MSc. Pharm         
Sub-Investigator: Martin Schmudermaier, MD         
Sub-Investigator: Michael H Andreae, MD         
Sub-Investigator: Hanna Opelt, MD         
Sub-Investigator: Stephan Stellnberger, MD         
Sub-Investigator: Juergen Sandkuehler, MD, PHD         
Sub-Investigator: Ruth Drdla, PHD         
Sponsors and Collaborators
Medical University of Vienna
Study Chair: Burkhard Gustorff, MD Medical University of Vienna
  More Information

Responsible Party: Professor Burkhard Gustorff, Vienna Human Pain Research Group, Department of Anaesthesia, Medical University of Vienna Identifier: NCT00789386     History of Changes
Other Study ID Numbers: VHPRG-RemiCaps2
Study First Received: November 10, 2008
Last Updated: May 20, 2009

Keywords provided by Medical University of Vienna:

Additional relevant MeSH terms:
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Adjuvants, Anesthesia
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics, General
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Dermatologic Agents processed this record on August 21, 2017